Inactive Instrument

News Regen BioPharma Inc OTC Bulletin Board

Equities

US75886M1027

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	Apr. 24	CI
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	Feb. 09	CI
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024	Feb. 05	PR
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Jan. 19	CI
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 20	CI
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program	Nov. 14	CI
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program	23-10-25	CI
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly	23-10-18	CI
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer	23-09-20	AQ
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies	23-09-19	CI
Regen BioPharma, Inc. announced that it has received $0.14875 million in funding	23-09-11	CI
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023	23-08-08	PR
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-07-25	CI
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-04-18	CI
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	23-02-07	AQ
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio	23-01-23	AQ
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	23-01-19	AQ
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-01-19	CI
Regen BioPharma, Inc. Announces Board Appointments	22-12-07	CI
Regen BioPharma : Private Placement - Form 8-K	22-11-21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Regen BioPharma Inc OTC Bulletin Board

Equities

US75886M1027

Summary

Filters